AI-generated analysis
Alantra Private Equity's decision to establish a €155 million continuation vehicle for Health in Code (HiC) underscores the firm’s commitment to supporting HiC through its next phase of growth, while simultaneously providing liquidity to existing investors at attractive returns. The continuation structure, led by Hayfin Capital Management and bolstered by international institutional support, positions HiC with long-term capital essential for scaling operations and accelerating market penetration both domestically and internationally.
The deal mechanics reflect a strategic alignment between Alantra PE and Hayfin, with the latter’s deep expertise in single-asset GP-led transactions further enhancing the credibility of this move. The transaction also includes Mérieux Equity Partners acquiring a 20% minority stake, adding valuable sector knowledge and international network capabilities to HiC's growth trajectory.
This continuation vehicle reshapes competitive dynamics within the clinical genetics space by fortifying HiC’s market position against rivals through enhanced financial stability and operational scale. With revenues more than doubling since Alantra PE's initial investment in 2020, HiC is now better equipped to leverage its expanded capital base for further consolidation and international expansion.
Post-close, key integration challenges will include harmonizing operations between the existing investor base and new stakeholders like Mérieux Equity Partners. Additionally, maintaining operational excellence while scaling internationally presents strategic risks that require careful management. However, with a proven track record of successful execution under Alantra PE's leadership, HiC is well-positioned to navigate these complexities and capitalize on growth opportunities in emerging markets.
Alantra, a European private equity firm, acquired Health in Code for $179m to support the healthcare software company’s next phase of growth with long-term capital and provide liquidity to existing investors. The deal was announced on February 12, 2026.
| Acquirer | Alantra (ES) |
|---|
| Target | Health in Code (ES) |
|---|
| Value | $179m |
|---|
| Type | Continuation vehicle |
|---|
| Closing date | February 12, 2026 |
|---|
| Buy-side advisor | Rede Partners |
|---|
| Sell-side advisor | Not disclosed |
|---|
| Legal (buy) | Not disclosed |
|---|
| Legal (sell) | Not disclosed |
|---|
Deal Mechanics
The continuation vehicle is a structured investment model that helps existing shareholders, including Hayfin and Mérieux Equity Partners, realize value while ensuring Health in Code continues to receive the financial support necessary for its strategic initiatives.
Strategic Rationale
The acquisition is designed to provide long-term capital to Health in Code, which operates within the rapidly evolving healthcare IT sector. By partnering with established investors like Hayfin and Mérieux Equity Partners, Alantra aims to leverage their expertise and financial backing for future growth.
Financial Context
The $179m deal reflects Alantra’s belief in Health in Code's potential, as well as the strategic importance of healthcare software solutions. The continuation vehicle structure is intended to align interests between existing shareholders and new investors, ensuring a steady flow of capital for expansion.
Outlook
With this investment, Health in Code will be positioned to accelerate its market penetration and product development, aiming to capitalize on the growing demand for digital health solutions. Alantra’s involvement signals confidence in HiC's leadership team and their vision for the company’s future.